Mylan, Akorn, Astex Pharma, and Forest Laboratories Under StockCall's Microscope

Mon Apr 8, 2013 8:09am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130408:nPn4089230


LONDON,  April 8, 2013  /PRNewswire/ --

A major trend to emerge in the healthcare industry since last year has been the
expiration of patents on several blockbuster drugs. The trend has benefited
companies such as Mylan Inc. (NASDAQ: MYL), and Akorn Inc. (NASDAQ: AKRX), which
focus generic drugs. For major drug manufacturers such as Astex Pharmaceuticals
Inc. (NASDAQ: ASTX), and biotechnology companies such as Forest Laboratories
Inc. (NYSE: FRX), increasing generic competition is a major concern. Meanwhile,
the healthcare industry is also evaluating the impact of President Obama's
Affordable Care Act (ACA), which was upheld by the Supreme Court last year.
Healthcare stocks ended on a mixed note on Friday as the broad market struggled
following dismal jobs report for the month of March. StockCall has released full
comprehensive research on MYL, AKRX, ASTX, and FRX and these free technical
analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Shares of Mylan Inc. ended nearly flat in Friday's trading session. The stock
traded between  $28.20 and $28.66  before finishing the day 0.03% lower at 
$28.63. Mylan's shares have had a decent run so far in 2013, gaining more than
4%. However, the stock has struggled in the last two weeks after failing to
break through  $31  resistance level. The company's shares have seen a series of
lows over the past two weeks, which is a bearish signal. The downbeat trend is
further confirmed by the stock's MACD chart. The stock has also slipped below
its 50-day moving average. Free technical analysis on MYL available by signing
up at

http://www.StockCall.com/MYL040813.pdf

Akorn Inc.'s shares ended flat in Friday's trading session. The stock traded
between  $13.25 and $13.51  before finishing the day at  $13.50. Akorn's shares
last week slipped below their 200-day moving average, which is a bearish signal.
The stock's MACD has also slipped below the signal line, further confirming the
negative trend. The company's shares currently have support at around  $13.25.
Year-to-date, the stock has gained more than 1%. Register today and access the
free research on AKRX at

http://www.StockCall.com/AKRX040813.pdf

Shares of Astex Pharmaceuticals Inc. rose sharply in trading on Friday even as
the broad market struggled. The stock touched an intra-day high of  $5.49 
before finishing the day 3.06% higher at  $5.39. Astex Pharma's shares are
currently trading close to their 52-week high of  $5.81. The stock has gained
more than 6.70% in the last three sessions. Year-to-date, the company's shares
have gained more than 85%, easily outperforming the broad market. The stock has
seen a series of highs over the past two weeks, which is a bullish signal. The
free report on ASTX can be downloaded by signing up now at

http://www.StockCall.com/ASTX040813.pdf

Shares of Forest Laboratories Inc. edged lower on Friday, tracking losses in the
broad market. The stock ended the day 0.37% lower at  $37.52  after touching an
intra-day low of  $37.08. Shares of FRX have traded sideways in the last few
weeks, struggling to break through  $38  resistance level. The stock is
currently trading above its 50-day and 200-day moving averages, which is a
bullish signal. However, the stock's MACD chart suggests that market sentiment
has turned bearish. Year-to-date, the stock has gained more than 6.20%. Free
report on FRX can be accessed by registering at

http://www.StockCall.com/FRX040813.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up
today to talk to our financial analyst at

http://www.stockcall.com   

SOURCE  StockCall.com


Contact Person: William T. Knight, Email: info@stockcall.com, Contact Number:
+1(646) 396-9857 (9:00 am EST - 01:30 pm EST)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.